{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:22:34Z","timestamp":1793679754013,"version":"4.5.1"},"reference-count":98,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:p>The field of biomarker discovery is rapidly expanding. The introduction of ultrasensitive immunoassays and the growing precision of genetic technologies are poised to revolutionise the assessment and monitoring of many diseases. Given the difficulties in imaging and tissue diagnosis, there is mounting interest in serum and cerebrospinal fluid biomarkers of peripheral neuropathy. Realised and potential fluid biomarkers of peripheral nerve disease include neuronal biomarkers of axonal degeneration, glial biomarkers for peripheral demyelinating disorders, immunopathogenic biomarkers (such as the presence and titre of antibodies or the levels of cytokines) and genetic biomarkers. Several are already starting to inform clinical practice, whereas others remain under evaluation as potential indicators of disease activity and treatment response. As more biomarkers become available for clinical use, it has become increasingly difficult for clinicians and researchers to keep up-to-date with the most recent discovery and interpretation. In this review, we aim to inform practising neurologists, neuroscientists and other clinicians about recent advances in fluid biomarker technology, with a focus on single molecule arrays (Simoa), chemiluminescent enzyme immunoassays (CLEIA), electrochemiluminescence (ECL), proximity extension assays (PEA), and microfluidic technology. We discuss established and emerging fluid biomarkers of peripheral neuropathy, their clinical applications, limitations and potential future developments.<\/jats:p>","DOI":"10.1136\/jnnp-2023-332031","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T17:20:31Z","timestamp":1697044831000},"page":"114-124","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":16,"title":["Ultrasensitive assay technology and fluid biomarkers for the evaluation of peripheral nerve disease"],"prefix":"10.1136","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4543-0162","authenticated-orcid":false,"given":"Roberto","family":"Bellanti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2102-6053","authenticated-orcid":false,"given":"Stephen","family":"Keddie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3174-6027","authenticated-orcid":false,"given":"Michael P","family":"Lunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2039-3457","authenticated-orcid":false,"given":"Simon","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,10,11]]},"reference":[{"key":"2024011107550745000_95.2.114.1","unstructured":"FDA-NIH Biomarker Working Group . BEST (biomarkers, endpoints, and other tools) resource [Internet]. silver spring (MD): food and Drug Administration (US). 2016. Available: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK326791"},{"key":"2024011107550745000_95.2.114.2","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","article-title":"Comparison of three Analytical platforms for Quantification of the Neurofilament light chain in blood samples: ELISA, Electrochemiluminescence immunoassay and Simoa","volume":"54","author":"Kuhle","year":"2016","journal-title":"Clinical Chemistry and Laboratory Medicine (CCLM)"},{"key":"2024011107550745000_95.2.114.3","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1111\/ene.15428","article-title":"Neurofilament light chain and total Tau in the differential diagnosis and Prognostic evaluation of acute and chronic inflammatory Polyneuropathies","volume":"29","author":"Kmezic","year":"2022","journal-title":"Euro J of Neurology"},{"key":"2024011107550745000_95.2.114.4","doi-asserted-by":"crossref","unstructured":"Arcaro M , Fenoglio C , Serpente M , et al . A novel automated Chemiluminescence method for detecting cerebrospinal fluid Amyloid-beta 1-42 and 1-40, total Tau and Phosphorylated-Tau: implications for improving diagnostic performance in Alzheimer\u2019s disease. Biomedicines 2022;10:2667. doi:10.3390\/biomedicines10102667","DOI":"10.3390\/biomedicines10102667"},{"key":"2024011107550745000_95.2.114.5","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0502-473"},{"key":"2024011107550745000_95.2.114.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0958-1669(02)00011-3"},{"key":"2024011107550745000_95.2.114.7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1586\/epr.11.78","article-title":"DNA-assisted protein detection Technologies","volume":"9","author":"Nong","year":"2012","journal-title":"Expert Rev Proteomics"},{"key":"2024011107550745000_95.2.114.8","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1007\/s00415-023-11624-2","article-title":"Neurofilament light chain levels indicate acute axonal damage under bortezomib treatment","volume":"270","author":"Cebulla","year":"2023","journal-title":"J Neurol"},{"key":"2024011107550745000_95.2.114.9","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410230407"},{"key":"2024011107550745000_95.2.114.10","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-323899"},{"key":"2024011107550745000_95.2.114.11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/jns.12319","article-title":"Serum Neurofilament light chain in chronic inflammatory Demyelinating polyneuropathy","volume":"24","author":"van Lieverloo","year":"2019","journal-title":"J Peripher Nerv Syst"},{"key":"2024011107550745000_95.2.114.12","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004932"},{"key":"2024011107550745000_95.2.114.13","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/jns.12350","article-title":"Plasma Neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary Transthyretin Amyloidosis","volume":"24","author":"Kapoor","year":"2019","journal-title":"J Peripher Nerv Syst"},{"key":"2024011107550745000_95.2.114.14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/13506129.2020.1815696","article-title":"Neurofilament light chain, a biomarker for polyneuropathy in systemic Amyloidosis","volume":"28","author":"Louwsma","year":"2021","journal-title":"Amyloid"},{"key":"2024011107550745000_95.2.114.15","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.clinph.2021.03.016","article-title":"Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study","volume":"132","author":"Frithiof","year":"2021","journal-title":"Clin Neurophysiol"},{"key":"2024011107550745000_95.2.114.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212045"},{"key":"2024011107550745000_95.2.114.17","doi-asserted-by":"crossref","unstructured":"Kim S-H , Choi MK , Park NY , et al . Serum Neurofilament light chain levels as a biomarker of Neuroaxonal injury and severity of Oxaliplatin-induced peripheral neuropathy. Sci Rep 2020;10. doi:10.1038\/s41598-020-64511-5","DOI":"10.1038\/s41598-020-64511-5"},{"key":"2024011107550745000_95.2.114.18","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/brain\/awac418","article-title":"Anti-pan-Neurofascin antibodies induce Subclass-related complement activation and Nodo-Paranodal damage","volume":"146","author":"Appeltshauser","year":"2023","journal-title":"Brain"},{"key":"2024011107550745000_95.2.114.19","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00125-022-05846-8","article-title":"Serum Neurofilament light chain: a novel biomarker for early diabetic sensorimotor polyneuropathy","volume":"66","author":"Maalmi","year":"2023","journal-title":"Diabetologia"},{"key":"2024011107550745000_95.2.114.20","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2012-303768"},{"key":"2024011107550745000_95.2.114.21","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/mus.25124","article-title":"Plasma Neurofilament heavy chain is not a useful biomarker in Charcot-Marie-tooth disease","volume":"53","author":"Rossor","year":"2016","journal-title":"Muscle Nerve"},{"key":"2024011107550745000_95.2.114.22","doi-asserted-by":"crossref","unstructured":"Qiao X , Zhang S , Zhao W , et al . Serum Phosphorylated Neurofilament-heavy chain, a potential biomarker, is associated with peripheral neuropathy in patients with type 2 diabetes. Medicine 2015;94:e1908. doi:10.1097\/MD.0000000000001908","DOI":"10.1097\/MD.0000000000001908"},{"key":"2024011107550745000_95.2.114.23","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-307672"},{"key":"2024011107550745000_95.2.114.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneumeth.2010.11.026"},{"key":"2024011107550745000_95.2.114.25","doi-asserted-by":"crossref","unstructured":"Gaiottino J , Norgren N , Dobson R , et al . Increased Neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One 2013;8:e75091. doi:10.1371\/journal.pone.0075091","DOI":"10.1371\/journal.pone.0075091"},{"key":"2024011107550745000_95.2.114.26","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0590"},{"key":"2024011107550745000_95.2.114.27","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00107"},{"key":"2024011107550745000_95.2.114.28","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1007\/s00125-021-05557-6","article-title":"Neuron-specific biomarkers predict hypo- and hyperalgesia in individuals with diabetic peripheral neuropathy","volume":"64","author":"Morgenstern","year":"2021","journal-title":"Diabetologia"},{"key":"2024011107550745000_95.2.114.29","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.bbadis.2006.09.003","article-title":"Neuronal intermediate filaments and ALS: A new look at an old question","volume":"1762","author":"Xiao","year":"2006","journal-title":"Biochim Biophys Acta"},{"key":"2024011107550745000_95.2.114.30","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(90)90832-V"},{"key":"2024011107550745000_95.2.114.31","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1002\/acn3.51419","article-title":"Evaluation of Peripherin in Biofluids of patients with motor neuron diseases","volume":"8","author":"Sabbatini","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"2024011107550745000_95.2.114.32","doi-asserted-by":"crossref","unstructured":"Keddie S , Smyth D , Keh RYS , et al . Peripherin is a biomarker of axonal damage in peripheral nervous system disease. Brain 2023:awad234. doi:10.1093\/brain\/awad234","DOI":"10.1093\/brain\/awad234"},{"key":"2024011107550745000_95.2.114.33","doi-asserted-by":"crossref","first-page":"16084","DOI":"10.1038\/nrdp.2016.84","article-title":"Traumatic brain injuries","volume":"2","author":"Blennow","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2024011107550745000_95.2.114.34","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jamaneurol.2019.1071","article-title":"Association of blood and cerebrospinal fluid Tau level and other biomarkers with survival time in sporadic Creutzfeldt-Jakob disease","volume":"76","author":"Staffaroni","year":"2019","journal-title":"JAMA Neurol"},{"key":"2024011107550745000_95.2.114.35","unstructured":"SpringerLink . Distribution of five clinically important Neuroglial proteins in the human brain. 2023. Available: https:\/\/link.springer.com\/article\/10.1186\/s13041-022-00935-6"},{"key":"2024011107550745000_95.2.114.36","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00401-017-1707-9","article-title":"Roles of Tau protein in health and disease","volume":"133","author":"Guo","year":"2017","journal-title":"Acta Neuropathol"},{"key":"2024011107550745000_95.2.114.37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01124-1"},{"key":"2024011107550745000_95.2.114.38","doi-asserted-by":"publisher","DOI":"10.1038\/nrn.2015.1"},{"key":"2024011107550745000_95.2.114.39","doi-asserted-by":"publisher","DOI":"10.1089\/neu.2014.3548"},{"key":"2024011107550745000_95.2.114.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.resuscitation.2012.07.027"},{"key":"2024011107550745000_95.2.114.41","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/acn3.50965","article-title":"Transmembrane protease Serine 5: a novel Schwann cell plasma marker for Cmt1A","volume":"7","author":"Wang","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"2024011107550745000_95.2.114.42","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/mus.21323","article-title":"Glial fibrillary acidic protein as a marker of axonal damage in chronic Neuropathies","volume":"40","author":"Notturno","year":"2009","journal-title":"Muscle Nerve"},{"key":"2024011107550745000_95.2.114.43","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-324445"},{"key":"2024011107550745000_95.2.114.44","doi-asserted-by":"crossref","unstructured":"Lleix\u00e0 C , Mart\u00edn-Aguilar L , Pascual-Go\u00f1i E , et al . Autoantibody screening in Guillain\u2013Barr\u00e9 syndrome. J Neuroinflammation 2021;18:251. doi:10.1186\/s12974-021-02301-0","DOI":"10.1186\/s12974-021-02301-0"},{"key":"2024011107550745000_95.2.114.45","doi-asserted-by":"crossref","unstructured":"Thomma RCM , Fokke C , Walgaard C , et al . High and persistent anti-Gm1 antibody titers are associated with poor clinical recovery in Guillain-Barr\u00e9 syndrome. Neurol Neuroimmunol Neuroinflamm 2023;10:e200107. doi:10.1212\/NXI.0000000000200107 Available: https:\/\/nn.neurology.org\/content\/10\/4\/e200107","DOI":"10.1212\/NXI.0000000000200107"},{"key":"2024011107550745000_95.2.114.46","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/mus.880170116","article-title":"Do Gm1 antibodies induce Demyelination","volume":"17","author":"Lange","year":"1994","journal-title":"Muscle Nerve"},{"key":"2024011107550745000_95.2.114.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2012.02.011"},{"key":"2024011107550745000_95.2.114.48","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1055\/s-0033-1334468","article-title":"Multifocal motor neuropathy","volume":"32","author":"Nowacek","year":"2012","journal-title":"Semin Neurol"},{"key":"2024011107550745000_95.2.114.49","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410240113"},{"key":"2024011107550745000_95.2.114.50","doi-asserted-by":"publisher","DOI":"10.1002\/mus.880170115"},{"key":"2024011107550745000_95.2.114.51","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181ff94c2"},{"key":"2024011107550745000_95.2.114.52","doi-asserted-by":"publisher","DOI":"10.1172\/JCI37338"},{"key":"2024011107550745000_95.2.114.53","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jneuroim.2019.01.003","article-title":"Clinical characterization of anti-Gq1B antibody syndrome in Korean children","volume":"330","author":"Yoon","year":"2019","journal-title":"J Neuroimmunol"},{"key":"2024011107550745000_95.2.114.54","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/mus.27071","article-title":"Ganglioside complex antibodies in an Indian cohort of Guillain-Barr\u00e9 syndrome","volume":"62","author":"Wahatule","year":"2020","journal-title":"Muscle and Nerve"},{"key":"2024011107550745000_95.2.114.55","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s00415-019-09308-x","article-title":"Antecedent infections in Fisher syndrome: sources of variation in clinical characteristics","volume":"266","author":"Koga","year":"2019","journal-title":"J Neurol"},{"key":"2024011107550745000_95.2.114.56","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awg233"},{"key":"2024011107550745000_95.2.114.57","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2012-302824"},{"key":"2024011107550745000_95.2.114.58","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3233\/JND-150078","article-title":"Diagnostic utility of auto antibodies in inflammatory nerve disorders","volume":"2","author":"Emilien","year":"2015","journal-title":"J Neuromuscul Dis"},{"key":"2024011107550745000_95.2.114.59","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/124.10.1968"},{"key":"2024011107550745000_95.2.114.60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054494"},{"key":"2024011107550745000_95.2.114.61","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.31.11.1480"},{"key":"2024011107550745000_95.2.114.62","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2020-002837"},{"key":"2024011107550745000_95.2.114.63","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-011-0237-4"},{"key":"2024011107550745000_95.2.114.64","doi-asserted-by":"publisher","DOI":"10.1007\/BF00319857"},{"key":"2024011107550745000_95.2.114.65","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/jns.12287","article-title":"Rituximab in chronic inflammatory Demyelinating Polyradiculoneuropathy with associated diseases","volume":"23","author":"Roux","year":"2018","journal-title":"J Peripher Nerv Syst"},{"key":"2024011107550745000_95.2.114.66","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2009.188912"},{"key":"2024011107550745000_95.2.114.67","doi-asserted-by":"crossref","unstructured":"Liberatore G , Giannotta C , Sajeev BP , et al . Sensitivity and specificity of a commercial ELISA test for anti-MAG antibodies in patients with neuropathy. J Neuroimmunol 2020;345:S0165-5728(20)30192-2. doi:10.1016\/j.jneuroim.2020.577288","DOI":"10.1016\/j.jneuroim.2020.577288"},{"key":"2024011107550745000_95.2.114.68","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14492"},{"key":"2024011107550745000_95.2.114.69","doi-asserted-by":"crossref","unstructured":"Keh RYS , Shah S , Lilleker JB , et al . Pragmatic guide to peripheral nerve disease and the role of clinical biomarkers. Pract Neurol 2022:pn-2022-003438. doi:10.1136\/pn-2022-003438","DOI":"10.1136\/pn-2022-003438"},{"key":"2024011107550745000_95.2.114.70","doi-asserted-by":"crossref","unstructured":"H\u00e4nggi P , Aliu B , Martin K , et al . Decrease in serum anti-MAG Autoantibodies is associated with therapy response in patients with anti-MAG neuropathy: retrospective study. Neurol Neuroimmunol Neuroinflamm 2022;9:e1109. doi:10.1212\/NXI.0000000000001109","DOI":"10.1212\/NXI.0000000000001109"},{"key":"2024011107550745000_95.2.114.71","doi-asserted-by":"crossref","unstructured":"Fehmi J , Vale T , Keddie S , et al . Nodal and Paranodal antibody-associated Neuropathies. Pract Neurol 2021:practneurol-2021-002960. doi:10.1136\/practneurol-2021-002960","DOI":"10.1136\/practneurol-2021-002960"},{"key":"2024011107550745000_95.2.114.72","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1212\/WNL.0000000000004773","article-title":"Neurofascin antibodies in autoimmune, genetic, and idiopathic Neuropathies","volume":"90","author":"Burnor","year":"2018","journal-title":"Neurology"},{"key":"2024011107550745000_95.2.114.73","doi-asserted-by":"crossref","unstructured":"Querol L , Rojas-Garc\u00eda R , Diaz-Manera J , et al . Rituximab in treatment-resistant CIDP with antibodies against Paranodal proteins [Internet]. Neurol Neuroimmunol Neuroinflamm 2015;2:e149. doi:10.1212\/NXI.0000000000000149 Available: https:\/\/nn.neurology.org\/content\/2\/5\/e149.short","DOI":"10.1212\/NXI.0000000000000149"},{"key":"2024011107550745000_95.2.114.74","doi-asserted-by":"crossref","unstructured":"Cortese A , Lombardi R , Briani C , et al . Antibodies to Neurofascin, Contactin-1, and Contactin-associated protein 1 in CIDP: clinical relevance of IgG Isotype. Neurol Neuroimmunol Neuroinflamm 2020;7:e639. doi:10.1212\/NXI.0000000000000639 Available: https:\/\/nn.neurology.org\/content\/7\/1\/e639","DOI":"10.1212\/NXI.0000000000000639"},{"key":"2024011107550745000_95.2.114.75","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-309916"},{"key":"2024011107550745000_95.2.114.76","doi-asserted-by":"crossref","unstructured":"Hashimoto Y , Ogata H , Yamasaki R , et al . Chronic inflammatory Demyelinating polyneuropathy with concurrent membranous nephropathy: an anti-Paranode and Podocyte protein antibody study and literature survey. Front Neurol 2018;9:997. doi:10.3389\/fneur.2018.00997 Available: https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2018.00997","DOI":"10.3389\/fneur.2018.00997"},{"key":"2024011107550745000_95.2.114.77","doi-asserted-by":"crossref","first-page":"E19","DOI":"10.1002\/mus.26392","article-title":"Neuro-renal syndrome\u201d related to anti-Contactin-1 antibodies","volume":"59","author":"Taieb","year":"2019","journal-title":"Muscle Nerve"},{"key":"2024011107550745000_95.2.114.78","doi-asserted-by":"crossref","unstructured":"Fehmi J , Davies AJ , Antonelou M , et al . Contactin-1 antibodies link autoimmune Neuropathies to nephrotic syndrome [Internet]. SSRN Journal 2020. doi:10.2139\/ssrn.3739819 Available: https:\/\/papers.ssrn.com\/abstract=3739819","DOI":"10.2139\/ssrn.3739819"},{"key":"2024011107550745000_95.2.114.79","doi-asserted-by":"crossref","unstructured":"Zhang X , Kira J-I , Ogata H , et al . Anti-Lgi4 antibody is a novel Juxtaparanodal autoantibody for chronic inflammatory Demyelinating polyneuropathy. Neurol Neuroimmunol Neuroinflamm 2023;10:e200081. doi:10.1212\/NXI.0000000000200081 Available: https:\/\/nn.neurology.org\/content\/10\/2\/e200081","DOI":"10.1212\/NXI.0000000000200081"},{"key":"2024011107550745000_95.2.114.80","doi-asserted-by":"crossref","unstructured":"Sakai K , Komai K , Yanase D , et al . Plasma VEGF as a marker for the diagnosis and treatment of Vasculitic neuropathy. J Neurol Neurosurg Psychiatry 2005;76:296. doi:10.1136\/jnnp.2004.047571","DOI":"10.1136\/jnnp.2004.047571"},{"key":"2024011107550745000_95.2.114.81","doi-asserted-by":"crossref","unstructured":"Pihan M , Keddie S , D\u2019Sa S , et al . Raised VEGF: high sensitivity and specificity in the diagnosis of POEMS syndrome. Neurol Neuroimmunol Neuroinflamm 2018;5:e486. doi:10.1212\/NXI.0000000000000486","DOI":"10.1212\/NXI.0000000000000486"},{"key":"2024011107550745000_95.2.114.82","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jpainsymman.2017.04.021","article-title":"Neuropathic pain and nerve growth factor in chemotherapy-induced peripheral neuropathy: prospective clinical-pathological study","volume":"54","author":"Velasco","year":"2017","journal-title":"J Pain Symptom Manage"},{"key":"2024011107550745000_95.2.114.83","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh348"},{"key":"2024011107550745000_95.2.114.84","doi-asserted-by":"crossref","unstructured":"Youk J , Kim Y-S , Lim J-A , et al . Depletion of nerve growth factor in chemotherapy-induced peripheral neuropathy associated with hematologic malignancies. PLOS ONE 2017;12:e0183491. doi:10.1371\/journal.pone.0183491","DOI":"10.1371\/journal.pone.0183491"},{"key":"2024011107550745000_95.2.114.85","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/bjh.12624","article-title":"Bortezomib-induced peripheral neuropathy is related to altered levels of brain-derived Neurotrophic factor in the peripheral blood of patients with multiple myeloma","volume":"164","author":"Azoulay","year":"2014","journal-title":"Br J Haematol"},{"key":"2024011107550745000_95.2.114.86","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s10549-015-3546-5","article-title":"Association between met-BDNF allele and vulnerability to paclitaxel-induced peripheral neuropathy","volume":"153","author":"Azoulay","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"2024011107550745000_95.2.114.87","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3988\/jcn.2019.15.4.511","article-title":"Prediction of chemotherapy-induced peripheral neuropathy in patients with lymphoma and myeloma: the roles of brain-derived Neurotropic factor protein levels and A gene polymorphism","volume":"15","author":"Azoulay","year":"2019","journal-title":"J Clin Neurol"},{"key":"2024011107550745000_95.2.114.88","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2015-001095"},{"key":"2024011107550745000_95.2.114.89","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2012-302451"},{"key":"2024011107550745000_95.2.114.90","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22166"},{"key":"2024011107550745000_95.2.114.91","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1212\/WNL.0000000000012266","article-title":"Micrornas as biomarkers of Charcot-Marie-tooth disease type 1A","volume":"97","author":"Wang","year":"2021","journal-title":"Neurology"},{"key":"2024011107550745000_95.2.114.92","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-021-00936-z"},{"key":"2024011107550745000_95.2.114.93","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-316689"},{"key":"2024011107550745000_95.2.114.94","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s00277-017-2968-z","article-title":"Detection of Myd88 L265P and WHIM-like Cxcr4 Mutation in patients with Igm Monoclonal Gammopathy related disease","volume":"96","author":"Cao","year":"2017","journal-title":"Ann Hematol"},{"key":"2024011107550745000_95.2.114.95","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16088"},{"key":"2024011107550745000_95.2.114.96","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.177444"},{"key":"2024011107550745000_95.2.114.97","doi-asserted-by":"crossref","unstructured":"Drandi D , Decruyenaere P , Ferrante M , et al . Nucleic acid biomarkers in Waldenstr\u00f6m Macroglobulinemia and Igm-MGUS: Current insights and clinical relevance. Diagnostics (Basel) 2022;12:969. doi:10.3390\/diagnostics12040969","DOI":"10.3390\/diagnostics12040969"},{"key":"2024011107550745000_95.2.114.98","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/jnc.15682","article-title":"The 2022 Lady Estelle Wolfson Lectureship on Neurofilaments","volume":"163","author":"Petzold","year":"2022","journal-title":"J Neurochem"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2023-332031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T15:56:41Z","timestamp":1704988601000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2023-332031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,11]]},"references-count":98,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,1,11]]},"published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1136\/jnnp-2023-332031"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2023-332031","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,11]]}}}